A Randomised Phase 2 Monotherapy Trial of Bemcentinib in the later line elderly Patients with Acute-Myeloid-Leukaemia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2021 According to a BerGenBio media release, this trial is expected to be initiated in H2 2022.
01 Apr 2019 According to a BerGenBio media release, the Company is proceeding with preparations for this late-stage bemcentinib monotherapy trial in acute myeloid leukaemia.This study is expected to start in the second half of 2019 and will aim to confirm previously reported monotherapy efficacy of bemcentinib in AML patients whose disease has progressed on standard of care therapy.
05 Dec 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com